1 Title page

- 2 Title
- 3 Validation of a simplified HPV genotyping assay designed for cervical screening in low-resource
- 4 settings
- 5 **Short title:** Simplified HPV genotyping test for low-resource settings
- 6 **Authors:** Kanan T. Desai^{1,2}, Kayode O. Ajenifuja³, Clement A. Adepiti³, Federica Inturrisi¹, Casey
- 7 Dagnall^{1,4}, Amanda C. Hoffman^{1,4}, Didem Egemen¹, Julia C. Gage¹, Nicolas Wentzensen¹, Silvia
- 8 de Sanjose^{1,5}, Mark Schiffman¹

9 Author's affiliation:

- ¹National Cancer Institute, Rockville, MD, USA
- ¹¹ ²Norwalk Hospital Internal Medicine Residency Program, Norwalk, CT, USA
- 12 ³Obafemi Awolowo University, Ile-Ife, Nigeria
- ⁴Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research,
- 14 Leidos Biomedical Research, Inc., Frederick, MD, USA
- 15 ⁵ISGlobal, Barcelona, Spain
- 16 **Corresponding Author:** Federica Inturrisi (<u>f.inturrisi@outlook.com</u>)
- 17 Keywords: Cervical cancer screening, HPV testing, HPV genotyping, point-of-care, LMICs
- 18 Abbreviations: CI, confidence interval; CIN, cervical intraepithelial neoplasia; CGR, Center for
- 19 Cancer Genomics Laboratory; DNA, deoxyribonucleic acid; HPV, human papillomavirus; IARC,
- 20 International Agency for Research on Cancer; IP, intellectual property; LBC, liquid-based
- 21 cytology; LMIC, low- and middle-income country; NCI, National Cancer Institute; NIH, National
- 22 Institutes of Health; PAVE, HPV-Automated Visual Evaluation; PCR, polymerase chain reaction;
- 23 RS, risk stratification; RUO, research-use-only; SPSS, statistical package for the social sciences;
- 24 WHO, World Health Organization.
- 25
- 26 Main text word count: 3860 words
- 27 Abstract word count: 300 words

28 Abstract

29 Introduction:

- 30 Human papillomavirus (HPV) genotype predicts cervical cancer risk, and genotyping could help
- 31 guide management of HPV positives as part of cervical screening. An isothermal amplification
- 32 HPV extended genotyping test (ScreenFire HPV RS assay) can assay up to 96 controls/samples in
- 33 one hour plus preparation time. A novel format with pre-aliquoted reagents and an anti-
- 34 contamination component (Zebra BioDome[™]) could simplify the HPV testing process by
- 35 substantially reducing the assay preparation time and the chances of post-amplification
- 36 contamination. We validated Zebra BioDome formulation prior to its clinical use.

37 Methods:

- 38 Residual provider-collected cervical samples (n=450) from a population-based study in rural
- 39 Nigeria were retested with ScreenFire, once using the standard assay version (liquid reagents
- 40 combined onsite) and twice with Zebra BioDome. HPV results with adequate DNA (N=427) were
- analyzed channel-by-channel and using the cervical cancer risk-based hierarchy of HPV type
- 42 channels (HPV16, else 18/45, else 31/33/35/52/58, else 39/51/56/59/68, else high-risk HPV
- 43 negative) to evaluate Zebra BioDome repeatability and accuracy against the standard version.
- 44 Results:
- 45 Zebra BioDome reduced the number of pipetting steps to run the ScreenFire HPV assay.
- 46 Following amplification, the BioDome material formed a sealant layer above the reaction
- 47 components. Zebra BioDome had excellent repeatability and agreement with the standard
- 48 version, both at the channel-specific analysis [positive percent agreement between 88.4%
- 49 (HPV39/51/56/59/68) and 100% (HPV16); negative percent agreement between 97.8%
- 50 (HPV31/33/35/52/58) and 100% (HPV39/51/56/59/68)] and hierarchical analysis (overall
- 51 agreement 97.2%).

52 **Conclusions:**

- 53 The assay version utilizing Zebra BioDome performed similarly to the previously validated
- 54 standard version of the ScreenFire HPV assay and is now undergoing field evaluation. This
- solution has the potential to reduce assay preparation time and risk of contamination,
- 56 providing a simpler, low-cost, near-point-of-care HPV testing and extended genotyping solution

- 57 for cervical screening in lower-resource settings. Potential application of Zebra BioDome
- 58 technology to other DNA amplification assays should be considered.

59 Main text

60 Introduction

61 Cervical cancer rates and deaths tend to be highest in regions with limited resources (1). The 62 World Health Organization (WHO) call to eliminate cervical cancer globally promotes human 63 papillomavirus (HPV) vaccination, HPV-based screening during mid-adulthood, and treatment of both precancerous and cancerous conditions (2). Highly sensitive HPV testing of self-collected 64 samples is being promoted worldwide (3), because of the crucial role of HPV in the 65 development of cervical cancer (4), and the pressing need to screen many millions of women. It 66 67 is impractical to treat every infected woman in high-prevalence areas, because HPV infections are extremely common and often benign. Most HPV infections are controlled by the immune 68 69 system within 1 to 2 years of detection, and only persistently detectable infections lead to precancer and cancer (4). Because HPV detection on population screening can be very common, 70 71 and follow-up to distinguish persistence is often impractical, a triage test to identify biomarkers 72 of persistent/progressive infections is necessary for prioritization of care by need. HPV typing is a promising means of triage, because the likelihood of progression depends on the HPV type 73 and varies significantly among the 13 high-risk HPV types (5,6) classified by the International 74 75 Agency for Research on Cancer (IARC) as Group 1 (known carcinogens) or Group 2A (probable 76 carcinogens) (7). Risk-based extended HPV typing is proposed to stratify HPV-positive women according to their risk of developing cervical cancer and to guide clinical management (6). 77

78 An isothermal DNA amplification technology-based ScreenFire HPV risk stratification (RS) assay

79 (Atila Biosystems Inc., Sunnyvale, CA, USA) can provide extended genotyping for 13 high-risk

80 HPV types in the four established risk channels: 16, 18/45, 31/33/35/52/58, and

39/51/56/59/68 (8,9). It was designed to support clinical management according to the risk of
cervical cancer associated with the grouped types, hence the emphasis on risk stratification, in
which the highest-risk positive channel is reported when multiple concurrent infections are
present. It is relatively rapid and low-cost, making it suitable for extended HPV genotyping
beyond high-resource settings. Its clinical accuracy has already been shown (8–11) and the
assay is currently undergoing field validation as part of the HPV-Automated Visual Evaluation

(PAVE) protocol in nine low- and middle-income countries (LMICs) worldwide (12). Two aspects 87 of performing the ScreenFire HPV RS assay emerged during the validation to date and are 88 89 addressed here: the need to further decrease the time and manual handling 90 needed to run the assay, particularly during assay preparation phase, and the risk of laboratory 91 contamination. Despite being a simple assay, the ScreenFire HPV RS test in its current format still requires that a trained laboratory technician carry out a number of preparatory steps: 92 93 thawing reagents, preparing the master mix (by combining reaction mix and primer mix), dispensing the master mix into reaction tubes, and then adding the sample (Figure 1A). These 94 steps involve pipetting small volumes of reagents and samples, demanding careful attention to 95 96 detail and increasing the risk of human error, cross-contamination, and variability in results. Moreover, these steps add to the overall time required for HPV testing, making single-day 97 screening strategies more difficult. 98

Moreover, like any other DNA amplification technique (13), ScreenFire HPV RS assay is 99 100 susceptible to contamination of the laboratory environment by amplified products. The 101 problem arises because the post-amplification concentration of amplicons in a positive sample/control can reach 100-1000 billion copies per microliter. If the tube content is not 102 strictly contained after amplification, the high concentration of amplicons can contaminate 103 laboratory surfaces, equipment, pipettors, and personal protective gear like gloves and 104 105 laboratory coats. Identifying and cleaning up this contamination is time-consuming and 106 resource-intensive, both in terms of labor and money, and it precludes HPV testing activities 107 until full decontamination has been verified.

To reduce the number of pipetting steps and mitigate the risk of contamination, the assay's manufacturer Atila BioSystems developed an assay format with pre-aliquoted reagents and an anti-contamination component, known as 'Zebra BioDome[™]'. This format removes the need for preparation and dispensing of the master mix, only requiring the addition of the lysate to the Zebra BioDome tubes (Figure 1B) as the two components of the master mix are suspended between gel matrix layers. The gel matrix melts during amplification enabling the mixing of

sample and reagents and solidifies again at the top of the reaction volume during cooling, thuscreating a physical barrier for the amplified products (Figure 1C).

This article aims to independently validate the Zebra BioDome version of the ScreenFire HPV RS assay by comparing it with the established standard liquid version of the assay and assessing its repeatability.

119

120 Materials and Methods

121 Study population and design

122 The present study drew from 1,339 residual cervical samples stored frozen in PreservCyt solution (Hologic, Marlborough, MA, USA), collected by providers from a population-based 123 screening project in rural Nigeria (Project Itoju) involving women aged 16 to 88 years (mean 124 [standard deviation] = 44.0 [15.8]). The methodology of the Project Itoju has been detailed 125 elsewhere (14). In brief, between 2009 and 2010, approximately 1,420 eligible women—who 126 were not pregnant, were sexually active, had not undergone a hysterectomy, were at least 15 127 years old, and had been residing in their household for more than 3 months—were invited from 128 129 homes in the village of Irun, Nigeria. Participants in the research effort provided written 130 informed consent. During the screening, locally trained nurses conducted cervical examinations and collected samples using a broom-type device and an endocervical brush, which were then 131 placed in PreservCyt for liquid-based cytology (LBC) and HPV testing. 132

One milliliter aliquots of the frozen residual cytology samples were tested in the United States 133 (Albert Einstein Cancer Center) for HPV using an AmpliTag Gold MY09-MY11 polymerase chain 134 reaction (PCR)-based test that included additional type-specific primers, and primers to amplify 135 a cellular beta-globin fragment as an internal control for amplification as previously 136 described (15). PCR products were genotyped with dot-blot hybridization using type-specific 137 138 probes for 13 high-risk and >20 other HPV types, using a semi-quantitative measure of signal strength (1-5 from lowest to highest) as a proxy of viral load (16). Of note, the PCR signal 139 strength variable (1-5) is not strictly linear, in that a signal strength of 5 has no upper bound 140

and is, on average, particularly strong. Samples were also tested for HPV16 and HPV18 using a
 research-use-only (RUO) HPV DNA test, the Luminex assay.

Out of the 1,339 residual samples, valid (i.e., adequate DNA) HPV results at the AmpliTag Gold 143 144 MY09-MY11 PCR were obtained for 1,305 samples. A small subset (n = 8) was unblinded and 145 sent to Atila BioSystems for updating the AmpFire assay chemistry to the ScreenFire RS HPV assay with its emphasis on sensitive detection of the most high-risk HPV types (8). Of the 146 remaining 1,297 masked samples with valid results, we selected all 356 samples that tested 147 positive for any HPV types (including low-risk types) by either PCR or HPV16/18 Luminex. 148 Additionally, we randomly chose 100 of 941 specimens that tested negative for all HPV types 149 (including low-risk) by both PCR and Luminex. These 456 samples were previously used to 150 151 redesign and validate the ScreenFire HPV RS assay in its current standard format (8). Out of the 152 456 samples, six were found to have insufficient residual material (i.e., no more volume), 153 leaving 450 usable samples.

These same 450 samples were retested with ScreenFire HPV RS assay using both the standard (9) and Zebra BioDome versions of the assay. Testing using the standard version was conducted at the US National Cancer Institute's (NCI) Cancer Genomics Research (CGR) laboratory with visiting Atila BioSystems laboratory scientists. Testing using the Zebra BioDome version was conducted at the Atila BioSystems Laboratory by Atila BioSystems scientists. The scientists were blinded to prior testing results and had no role in the analysis or reporting of the experiments.

160 ScreenFire HPV testing

As per manufacturer's protocol, ScreenFire HPV RS assay can be used with dry swab samples, cervical cell suspension, FFPE slice samples, and purified DNA samples. For the work presented here, the protocol for cervical cell suspension was used, plus pre-processing steps to prepare the frozen residual specimens. Initially, 1 mL of cervical cell suspension in PreservCyt was transferred to a 1.5 mL tube and centrifuged at maximum speed for 15 minutes. The supernatant was discarded, and 100 μL of 1X lysis buffer was added to the pellet. The mixture was vortexed thoroughly to resuspend the cells. The resuspended cell pellets were then

transferred to 96-well PCR plates, incubated at 95°C for 15 minutes, allowed to cool to room
 temperature, and stored at -20°C for future use.

The plates were thawed at room temperature prior to testing with ScreenFire HPV RS assay.
This was done twice on one Powergene 9600 real-time PCR machine, once using the standard
liquid version and once using the Zebra BioDome version, and once on a second Powergene
machine using the Zebra BioDome version.

For testing with the standard liquid version, 5 µL of the prepared specimen (lysate) was
combined with 20 µL of freshly prepared master mix (containing reaction mix and primer mix)
in a 96-well PCR plate using a pipette. For testing with the Zebra BioDome version, 10 µL of the
lysate was added to each well using the technique described below. Positive and negative
template controls were included in each run. The plates or tube strips were sealed or capped,
gently vortexed, and centrifuged to ensure that all liquid settled at the bottom of the wells.

180 The plates or Zebra BioDome tube strips were then placed into the Powergene 9600 real-time

181 PCR machines, set to the isothermal program mode (60°C for 60 cycles of 1 minute each).

182 Fluorescence signals were detected using CY5 for the HPV16 channel, ROX for the HPV18/45

183 channel, CY5.5 for the HPV31/33/35/52/58 channel, FAM for the HPV39/51/56/59/68 channel,

and HEX for the human beta-globin gene as the internal control channel. A sample was deemed

positive for an HPV type (group) if a signal was detected in the corresponding HPV channel

186 within 60 minutes, regardless of the HEX channel signal. If no signal was detected in any of the

187 HPV channels within 60 minutes, a signal in the HEX channel was required for a certain sample

to be considered a valid HPV negative. If no signal was detected in any of the channels including

189 the HEX channel, a sample was considered invalid suggesting inadequate DNA in the reaction.

190 Zebra BioDome technology

191 Zebra BioDome is a proprietary format for isothermal amplification assays by Atila BioSystems.

192 It features layers of reaction mix and primer mix separated by the BioDome anti-contamination

193 gel matrix, with an additional BioDome layer on top for stability and containment. This assay

194 format comes as prepacked reaction tube strips covered by an adhesive film to prevent195 evaporation (Figure 1C-i).

196 The version of Zebra BioDome described here is penetrable, meaning that at room 197 temperature, the gel matrix is semi-solid – solid enough to prevent loss of the reaction mix, but soft enough to be pierced with a standard pipette tip. Users only need to remove the adhesive 198 199 film and pipette the lysate into the reaction tube. A standard volumetric pipette with a 200 disposable tip (avoiding very narrow tips to prevent gel matrix blockage) is used to insert the 201 sample/control to the bottom of the Zebra BioDome tube. Once the pipette tip touches the bottom, the pipettor is slightly withdrawn to allow dispensing of the lysate within the primer 202 203 mix layer. The pipette is then removed and visually inspected to ensure no clogging of residual 204 liquid in the tip. If clogging occurs, the volume transfer of 10 µL lysate is repeated into the same Zebra BioDome tube. 205

206 The gel matrix melts during amplification at 60°C enabling the mixing of the reaction

207 components and re-solidifies at the top of the reaction during cooling, thus creating a physical

208 barrier for the amplified products (Figure 1C-ii) and resulting in a sealed reaction chamber.

209 Statistical analysis

Valid ScreenFire HPV results were obtained for 427 out of 450 samples for both the standard
and Zebra BioDome versions, which were included in the analysis. The remaining 23 were
excluded from the analytical sample because of invalid results on either or both assay versions
(7 invalids by Zebra BioDome, 7 invalids by standard, 9 invalids by both).

Analyses were done to assess the repeatability of Zebra BioDome when testing on two different
Powergene instruments and to compare the HPV results of Zebra BioDome to those of the
standard assay version.

Two types of analyses were conducted. First, channel-by-channel in a non-hierarchical fashion, acknowledging that a sample could test positive for multiple HPV channels. Then, hierarchically using the risk-based grouping of HPV genotype channels intrinsic to ScreenFire's design. In the hierarchical analysis, HPV results were categorized as HPV16 positive, otherwise positive for

HPV18/45 (if HPV16 was not detected), otherwise positive for HPV31/33/35/52/58 (if
HPV16/18/45 were not detected), otherwise positive for HPV39/51/56/59/68, and otherwise
negative for the 13 high-risk types.

224 Positive and negative agreement statistics were calculated, with 95% confidence intervals (CI) 225 estimated under normal approximation. Agreement statistics for the repeatability analysis were calculated based on either replicate positivity/negativity. Agreement statistics for the 226 comparison of Zebra BioDome against the standard version were calculated using the standard 227 assay version as the reference. Additionally, McNemar's test for asymmetry was computed for 228 the channel-specific analysis. The analyses were adjusted back to the original sample by 229 weighting HPV negatives (i.e., 100 negatives were weighted by 9.41 for 941 negatives in the 230 231 original sample) while retaining channel-specific estimates.

232 Discrepancies between the Zebra BioDome version and the standard version were investigated

by examining PCR and Luminex results, as well as histopathology and LBC results when

available. Data on valid histopathology and/or LBC were available for 409 samples and both

missing for 18 samples. A reference case was defined as HPV16/18/45/31/33/35/52/58 PCR

positive for high-grade cervical intraepithelial neoplasia grade 2 or worse (CIN2+) on

237 histopathology or LBC, and in addition HPV16 PCR positive for low-grade/equivocal lesions on

histopathology or LBC. A reference control was defined as PCR high-risk HPV negative and

neither histology nor LBC positive. Following these definitions, we identified 29 definite cases

and 206 definite controls. 174 fell between the definitions of definite cases/controls.

Sensitivity analyses were carried out by restricting to HPV results of the study population of
women within the age range of 25 to 49 years.

All analyses were carried out using Microsoft Excel, the Statistical Package for the Social

Sciences (SPSS) (version 1.0.0.1089), and R Statistical Software (version 4.3.0).

246 Results

247 **Repeatability**

248 There was excellent agreement between the two replicates of ScreenFire HPV testing with the

- 249 Zebra BioDome version on Powergene instrument 1 vs instrument 2 across all channels in the
- non-hierarchical analysis (Table 1). The replicate on instrument 2 showed a slight, but non-
- significant, increase in positivity compared to that on instrument 1 for the HPV31/33/35/52/58
- channel. Repeatability was excellent also in the hierarchical analysis (not shown).

253 Channel-specific agreement

254 The number of invalid results was similar when using Zebra BioDome and the standard assay 255 version of the ScreenFire assay: 7 invalids by Zebra BioDome, 7 invalids by standard, 9 invalids 256 by both. Among the 427 valid results by both, there was very good agreement between the 257 Zebra BioDome version and the standard version across all channels in the non-hierarchical 258 analyses (Table 2). Zebra BioDome showed a slight, but non-significant, increase in positivity compared to the standard version for the HPV16 and HPV31/33/35/52/58 channels. 259 260 Conversely, the standard version exhibited a slight, but non-significant, increase in positivity for 261 the HPV39/51/56/59/68 channel. Additional positives detected by either version of the assay 262 did not show specific cross-reactivity patterns with other high-risk or low-risk HPV types 263 identified by PCR except for the possible chance finding that three of the seven additional 264 positives by Zebra BioDome for HPV31/33/35/52/58 were positive for HPV53. The two 265 additional positives by Zebra BioDome in the HPV16 channel were positive for HPV16 by either 266 PCR or Luminex. Similar agreement in the channel-specific analysis was found when repeating 267 the analysis only on the age range of 25 to 49 years and when using the results of the Zebra BioDome replicate on Powergene instrument 2 (not shown). 268

269 Hierarchical agreement

270 There was excellent agreement between the Zebra BioDome version and the standard version

- of the ScreenFire assay also in the hierarchical analyses (Table 3), which is relevant for risk-
- 272 based clinical management. Following the hierarchical distribution of HPV channels by the

- standard version, Zebra BioDome detected 25 out of 25 (100%) HPV16 positives; 24 out of 25
- 274 (96.0%) HPV18/45 positives in the absence of HPV16; 88 out of 90 (97.8%) HPV31/33/35/52/58
- positives in the absence of HPV16, or 18/45; 35 out of 36 (97.2%) otherwise
- 276 HPV39/51/56/59/68 positives. The overall agreement between the Zebra BioDome version vs
- the standard version was 97.2% (95% CI: 95.6%-98.8%) without sampling weights and 99.1%
- 278 (95% CI: 98.6%-99.6%) with sampling weights (Table 3). Similar agreement in the hierarchical
- analysis was found when repeating the analysis using the results of the Zebra BioDome
- replicate performed on Powergene instrument 2 (not shown).
- Among the 29 reference cases, both the Zebra BioDome and the standard versions of the
- 282 ScreenFire assay detected 27 cases. Both versions missed the same two (6.9%) cases: one
- positive for HPV16 and one positive for HPV31/33/35/52/58 by PCR.
- Among the 206 reference controls, 13 (6.3%) were positive on both the Zebra BioDome and the
- standard versions of the ScreenFire assay. The Zebra BioDome version identified an additional
- three positives in the HPV31/33/35/52/58 channel.
- 287

288 Discussion

- 289 Our results showed that the Zebra BioDome version of the ScreenFire HPV RS assay had
- 290 excellent repeatability and agreement with the standard version of the assay, for each of the
- 291 four type groups defined by the assay individually and hierarchically. Small differences in
- channel positivity and invalid results were seen but none were statistically significant.
- The validation presented here aimed at comparing the novel Zebra BioDome version of ScreenFire HPV RS assay with the established standard version of the assay and assessing its repeatability on stored clinician-collected specimens under ideal laboratory conditions. A reallife trial of the clinical performance of Zebra BioDome post-shipping under realistic simpler laboratory conditions is beyond the scope of this work and is being addressed in ongoing field evaluation.

The Zebra BioDome version of the ScreenFire HPV RS assay was designed to manage the reality of HPV testing in LMICs, which is the need for accurate, rapid tests that allow single-day screening strategies for cervical cancer. As compared to the standard version of the ScreenFire HPV assay (8,9), Zebra BioDome seems to offer several advantages given its formulation with pre-aliquoted reagents and an anti-contamination component.

First, it eliminates the need for master mix preparation and aliquoting, hence reducing the
number of manual pipetting steps. This translates into reduced hands-on time for assay
preparation and reduced variability due to potentially unequal manually pipetted volumes (i.e.,
unequal volumes of primer mix and reaction mix combined during preparation of master mix,
and/or unequal volumes of master mix dispensed in the reaction wells). The only manual
pipetting step is the addition of 10 µL of lysate to the Zebra BioDome tube.

310 Second, the Zebra BioDome version reduces the risk of post-amplification contamination by 311 sealing the products with the BioDome matrix material. Contamination of amplified PCR products in a molecular biology laboratory space is a critical concern, common to all PCR-based 312 techniques (13). The assay's high sensitivity means that even small amounts of DNA can be 313 314 amplified, leading to a high number of copies post-amplification with a risk of leakage. Contamination is very damaging because it compromises the trustworthiness of results due to 315 false positives leading to incorrect interpretations and because it potentially invalidates the 316 317 entire laboratory due to the need to decontaminate and repeat experiments, wasting time and resources. Separately from the work presented here, a few Zebra BioDome tubes were opened 318 post-reaction, swabbed from the inside and re-run with ScreenFire HPV assay. They were found 319 to have minimal to no amplification, thus demonstrating effective reduction of contamination 320 with amplified products. By reducing the risk of contamination, the BioDome matrix increases 321 the reliability of HPV results for clinical management. Besides the anti-contamination role, this 322 matrix also acts as stabilizer of the Zebra BioDome formulation because it separates the layers 323 324 of pre-aliquoted reagents (i.e., reaction mix and primer mix) avoiding their mixing and it creates 325 a barrier from the air in the tube.

The formulation of Zebra BioDome may present a versatile and cost-effective solution for a
 wide range of DNA amplification techniques besides HPV, particularly at the table-top level. In

fact, the pre-aliquoted reagents and anti-contamination components are applicable to other
endpoint DNA amplification assays, potentially providing a broader application in research and
diagnostic settings. This innovation could prove instrumental in addressing generic problems of
molecular biology testing, such as assay preparation time and risk of post-amplification
contamination, and in advancing the accessibility of molecular testing in all settings where cost
and contamination control are critical.

The additional advantages of Zebra BioDome do not compromise those that are characteristic 334 of the ScreenFire HPV RS assay in its original formulation (8,9). Most importantly, the risk-based 335 hierarchy of HPV type channels because of the great difference in risk of cervical cancer 336 associated with HPV types (9). Hence, in case of positivity for multiple HPV channel, clinical 337 338 management is better directed following the hierarchical reading of the type groups: HPV16 339 positive, otherwise positive for HPV18 or HPV45 (if HPV16 was not detected), otherwise positive for HPV31/33/35/52/58 (if HPV16/18/45 were not detected), otherwise positive for 340 HPV39/51/56/59/68, and otherwise negative. Like the standard version, the Zebra BioDome 341 version allows for detection of HPV and a human DNA control directly from clinical specimens 342 without the need for DNA extraction and is compatible with dry self-collected samples without 343 requiring collection media. It also allows for flexibility to run up to 96 samples/controls without 344 product wastage (i.e., the pre-aliquoted strips of 8-tubes can be used in multiples of 8 or cut as 345 346 needed). These optimizations do not translate in additional costs compared to the standard version (approx. \$6 per test for scale-up). For transport and storage, the space requirement is 347 approximately unchanged while the temperature should be kept cold (recommended 2-8°C). A 348 note of caution goes for the transportation conditions because high temperatures may cause 349 disruption of the layers and invalidate the use of the product due to premature mixing of 350 351 reagents, hence the importance of maintaining a cold chain and implementing temperature checks for this penetrable version of Zebra BioDome. In the future, a re-formulation may be 352 353 considered to allow greater stability at warm temperatures and to remove the need of cold 354 chain.

- Following this positive evaluation, Zebra BioDome has been introduced at PAVE study sites
- using ScreenFire HPV RS assay (12). This field-evaluation will address the assay's clinical
- 357 accuracy and will evaluate its real-world use across a wide range of laboratory settings.

358 Conclusions

- In conclusion, the Zebra BioDome version of the ScreenFire HPV assay evaluated here has
- 360 demonstrated accurate risk-based genotype grouping while simplifying the HPV testing process
- 361 and reducing the risk of laboratory contamination. If validated in real-world settings, the assay
- 362 will be an example of a rapid HPV extended genotyping solution for resource-limited settings as
- 363 part of the ultimate public health goal to accelerate cervical cancer prevention. The formulation
- 364 may also have potential application for other DNA amplification assays.

365

366 Additional details

367 Conflict of Interest: The authors declare no conflict of interest. Atila BioSystems had no role in

the design, analysis, interpretation or drafting of this article.

369 **Funding source:** NCI Cancer Moonshot; NIH Intramural Research Program.

370 Data availability statement: The data that support the findings of our study are available from

the corresponding author upon reasonable request.

372 Ethics statement: Both Nigerian and National Cancer Institute (NCI, US) institutional review

boards (IRBs) (NCT 00804466) approved the original study protocol that included consent for

374 specimen storage for future research.

375 Authors contributions: Conceptualization, Mark Schiffman, Silvia de Sanjosé, Kanan T. Desai,

376 Federica Inturrisi; methodology, Mark Schiffman, Kanan T. Desai, Silvia de Sanjosé, Federica

- 377 Inturrisi, Didem Egemen; formal analysis, Kanan T. Desai, Federica Inturrisi, Didem Egemen;
- 378 Itoju field investigation, Mark Schiffman, Kayode O. Ajenifuja, Clement A. Adepiti, Julia C. Gage,
- 379 Nicolas Wentzensen; resources, Mark Schiffman, Kayode O. Ajenifuja, Clement A. Adepiti,
- 380 Nicolas Wentzensen; data curation, Kayode O. Ajenifuja, Julia C. Gage, Clement A. Adepiti,
- 381 Kanan T. Desai; laboratory evaluation, Amanda C. Hoffman, Casey L. Dagnall; writing—original

- draft preparation, Kanan T. Desai, Mark Schiffman, Silvia de Sanjosé, Federica Inturrisi;
- 383 writing—review and editing, all. All authors have read and agreed to the published version of
- the article.

386 References

- International Agency for Research on Cancer. World Health Organization. GCO Cancer 387 1. Today. 2021. Available from: https://gco.iarc.fr/today/ 388 389 2. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020. Available from: 390 https://www.who.int/publications/i/item/9789240014107 391 392 3. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Geneva: World Health Organization. 2021. 393 394 4. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus 395 and cervical cancer. Lancet. 2007 Sep;370(9590):890-907. de Sanjosé S, Serrano B, Tous S, Alejo M, Lloveras B, Quirós B, et al. Burden of Human 396 5. Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 397
- 398 58. JNCI cancer Spectr. 2018 Oct;2(4):pky045.
- Demarco M, Hyun N, Carter-Pokras O, Raine-Bennett TR, Cheung L, Chen X, et al. A study
 of type-specific HPV natural history and implications for contemporary cervical cancer
 screening programs. EClinicalMedicine. 2020 May;22:100293.
- 402 7. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No.100B. Lyon,
 403 France: World Health Organization. 2012.
- Besai KT, Adepiti CA, Schiffman M, Egemen D, Gage JC, Wentzensen N, et al. Redesign of
 a rapid, low-cost HPV typing assay to support risk-based cervical screening and
 management. Int J cancer. 2022 Oct;151(7):1142–9.
- Inturrisi F, de Sanjosé S, Desai KT, Dagnall C, Egemen D, Befano B, et al. A rapid HPV
 typing assay to support global cervical cancer screening and risk-based management: a
 cross-sectional study. Int J cancer. 2024 Jan;154(2):241–50.
- Hou J, Belinson JL, Du H, Li C, Zhang W, Zhang L, et al. AmpFire HPV and ScreenFire RS
 HPV validation trial. Am J Clin Pathol. 2024 Jun;161(6):535–42.
- Mungo C, Guliam A, Chinula L, Inturrisi F, Msowoya L, Mkochi T, et al. Comparison of the
 ScreenFire and Xpert HPV assays for the detection of human papillomavirus and cervical
 precancer among women living with HIV in Malawi. Infect Agent Cancer. 2024
 May;19(1):24.
- 416 12. de Sanjosé S, Perkins RB, Campos N, Inturrisi F, Egemen D, Befano B, et al. Design of the
 417 HPV-automated visual evaluation (PAVE) study: validating a novel cervical screening
 418 strategy. Elife. 2024 Jan;12.
- 419 13. Borst A, Box ATA, Fluit AC. False-positive results and contamination in nucleic acid
 420 amplification assays: suggestions for a prevent and destroy strategy. Eur J Clin Microbiol
 421 Infect Dis. 2004 Apr;23(4):289–99.
- 422 14. Gage JC, Ajenifuja KO, Wentzensen NA, Adepiti AC, Eklund C, Reilly M, et al. The age423 specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural
 424 Nigeria: implications for screen-and-treat strategies. Int J cancer. 2012 May;130(9):2111–
 425 7.
- 426 15. Castle PE, Schiffman M, Gravitt PE, Kendall H, Fishman S, Dong H, et al. Comparisons of
 427 HPV DNA detection by MY09/11 PCR methods. J Med Virol. 2002 Nov;68(3):417–23.
- 428 16. Gravitt PE, Kovacic MB, Herrero R, Schiffman M, Bratti C, Hildesheim A, et al. High load

- 429 for most high risk human papillomavirus genotypes is associated with prevalent cervical 430 cancer precursors but only HPV16 load predicts the development of incident disease. Int
- 431 J cancer. 2007 Dec;121(12):2787–93.

433 Tables

434

- 435 Table 1: Channel-specific repeatability of Zebra BioDome version of ScreenFire HPV RS assay,
- 436 run on Powergene1 and Powergene2, amongst 426[#] samples with valid results

Zebra BioDome ScreenFire HPV results: Powergene instrument 1/instrument 2	+/+ (N)	-/+ (N)	+/- (N)	-/- (N)	Overall positive agreement [95% CI]	Overall negative agreement [95% CI]	McNemar p-value
HPV16	27	0	0	399	100%	100%	NA [*]
HPV18/45	26	0	0	400	100%	100%	NA [*]
HPV31/33/35/52/58	103	3 ^a	7 ^b	313	91.2% [85.9%-96.4%]	96.9% [95.0%-98.8%]	0.34
HPV39/51/56/59/68	35	4 ^c	3 ^d	384	83.3% [72.1%-94.6%]	98.2% [96.9%-99.5%]	1.00
Agreement on overall HPV positivity (high-risk 13), irrespective of channel	175	5	6	240	94.1% [90.7%-97.5%]	95.6% [93.1%-98.2%]	1.00

437

438 [#]Excluding invalids on either replicate

^{*}McNemar test statistic cannot be derived because the disagreement is zero

^aThree positives on PCR: one for HPV58 (signal strength=2), one for HPV35 (signal strength=2), one for

441 HPV52 (signal strength=2)

^b Three positives on PCR: one for HPV35 (signal strength=3), one for HPV31 (signal strength=1), one for

443 HPV58 (signal strength=2)

444 ^cTwo positives for HPV68 (signal strength=4 and 5) on PCR

^dOne positive for HPV68 (signal strength=3) and one positive for HPV51 (sign strength=1) on PCR

- 447 Table 2: Channel-specific agreement (non-hierarchical) between Zebra BioDome (run on
- 448 Powergene1) and the standard version of ScreenFire HPV RS assay amongst 427 samples with
- 449 valid results by both versions

ScreenFire HPV results: Zebra BioDome (Powergene instrument 1)/Standard	+/+ (N)	-/+ (N)	+/- (N)	-/- (N)	Positive agreement with standard as reference [95% CI]	Negative agreement with standard as reference [95% CI]	McNemar p-value
HPV16	25	0	2 ^ª	400	100%	99.5% [98.8%-100%]	0.48
HPV18/45	25	1 ^b	1 ^b	400	96.2% [88.8%-100%]	99.8% [99.3%-100%]	1.00
HPV31/33/35/52/58	104	1 ^c	7 ^d	315	99.0% [97.2%-100%]	97.8% [96.2%-99.4%]	0.08
HPV39/51/56/59/68	38	5 ^e	0	384	88.4% [78.8%-98.0%]	100%	0.07
Agreement on overall HPV positivity (high-risk 13), irrespective of channel	174	2	8	243	98.9% [97.3%-100%]	96.8% * [94.6%-99.0%]	0.11

450

^aOne of the two was positive for HPV16 on Luminex; the other was positive for HPV16 on PCR (signal
 strength=2)

453 ^bAdditional positives on Zebra BioDome or standard version were positive for HPV18 on PCR (signal

454 strength=2-3)

455 ^cOne Positive for HPV31 on PCR (signal strength=2)

^dFour positives on PCR: one for HPV52 (signal strength=1), one for HPV35 (signal strength=2), two for
 HPV58 (signal strength=2); three additional were positive for HPV53

458 ^eThree positives on PCR: two for HPV68 (signal strength= 4-5), one for HPV59 (signal strength=3)

459 *Overall negative agreement was 96.8% [94.6%-99.0%] without sampling weights and was estimated to

460 be 99.3% [98.8%-99.8%] after applying sampling weights for negatives.

462 Table 3: Hierarchical agreement between Zebra BioDome and the standard version of

463 ScreenFire HPV RS assay according to HPV risk groups amongst 427 samples with valid results

464 **by both versions**

Screer	Fire HPV results:	Standard								
Zebra BioDome (Powergene instrument 1)/Standard		HPV 16	else HPV 18/45	else HPV 31/33/35/52/58	else HPV 39/51/56/59/68	else high- risk 13 negative	Total for Zebra BioDome			
Zebra BioDome	HPV16	25	0	1	0	1	27			
	column%	100%	0%	1.1%	0%	0.4%	6.3%			
	else HPV18/45	0	24	0	0	1	25			
	column%	0%	96.0%	0%	0%	0.4%	5.9%			
	else	0	1	88	0	6	95			
	HPV31/33/35/52/58									
	column%	0%	4.0%	97.8%	0%	2.4%	22.2%			
	else	0	0	0	35	0	35			
	HPV39/51/56/59/68									
	column%	0%	0%	0%	97.2%	0%	8.2%			
	else high-risk 13	0	0	1	1	243	245			
	negative									
	column%	0%	0%	1.1%	2.8%	96.8% *	57.4%			
	Total for standard	25	25	90	36	251	427 **			

465

466 Highlighted in gray are concordant HPV risk group results.

^{*}Overall negative agreement was 96.8% without sampling weights and 99.3% after applying sampling

468 weights for negatives.

^{**}Overall agreement was 97.2% without sampling weights and 99.1% after applying sampling weights for

470 negatives.

472 Figures

- 474 Figure 1: Steps to run the ScreenFire HPV RS assay on the Powergene instrument using dry
- swab samples following the PAVE study protocol (12). A) Assay in its standard liquid version
- 476 (the blue box highlights the steps impacted by the introduction of Zebra BioDome). B) Assay
- in the novel Zebra BioDome version. C) Details of the Zebra BioDome version before (i) and
- 478 after (ii) amplification.

